FDA Advisers Vote in Favor of Infant RSV Drug | TIME
AstraZeneca and Sanofi's drug, Beyfortus, for preventing RSV in infants, received unanimous FDA advisory panel support. It's a single-dose, long-acting monoclonal antibody aimed at newborns and infants during their first RSV season. The panel also supported its use for children up to two years old. The drug is already approved in the U.K., EU, and Canada.
Reference News
FDA Advisers Vote in Favor of Infant RSV Drug | TIME
AstraZeneca and Sanofi's drug, Beyfortus, for preventing RSV in infants, received unanimous FDA advisory panel support. It's a single-dose, long-acting monoclonal antibody aimed at newborns and infants during their first RSV season. The panel also supported its use for children up to two years old. The drug is already approved in the U.K., EU, and Canada.